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ABSTRACT
This study determined nasopharyngeal (NP)
carriage rates of Streptococcus pneumoniae among
healthy Estonian children, aged 1–7 years, and
characterised the serotype ⁄ serogroup distribution
and antibiotic susceptibility rates. NP swabs were
collected from 685 previously healthy children
attending 29 day care centres during the winters
of 1999–2000 and 2003. The NP carriage rate of
S. pneumoniae was 44%. Rates of penicillin and
erythromycin non-susceptibility were low (both
6%), but high (67%) rates of co-trimoxazole
resistance were found. Among the pneumococcal
serotypes identified, 64% were included in
or cross-reacted with the licensed heptavalent
pneumococcal vaccine.
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Limited data exist concerning the distribution of
penicillin-non-susceptible Streptococcus pneumoniae
(PNSP) in countries of the former Soviet Union.
In Russia, despite erratic use of antibiotics in the
past, the rate of PNSP has remained at <10%, but
high levels of erythromycin resistance have been
reported in some areas [1,2]. A low rate of PNSP
was also revealed by a previous study conducted
in Estonia during the late 1990s [3]. The aim of the
present study was to determine the nasopharyn-
geal (NP) carriage rate, antibiotic susceptibility
patterns and serotype distribution of S. pneumoniae
among children in Estonia, and to identify the
risk-factors associated with the carriage of
non-susceptible strains of S. pneumoniae before
the introduction of pneumococcal immunisation.
The study was conducted in three Estonian
towns (Tallinn, Tartu and Jo˜hvi ⁄Kohtla-Ja¨rve)
during the winters of 1999–2000 and 2003. NP
swabs were collected from 685 healthy children,
aged 1–7 years, who attended 29 different day
care centres. Parents or guardians completed a
questionnaire seeking information concerning
medical history and antibiotic treatment during
the previous 6 months. The study was approved
by the Ethical Committee of Tartu University.
Specimens were collected perinasally, using a
sterile swab with a flexible aluminium shaft and a
dry calcium alginate tip (Eurotubo; Industrias
Aulabor, Barcelona, Spain), and were sent to the
microbiology laboratory in Stuart transport med-
ium within 8 h of collection. All swabs were then
cultured on selective sheep blood agar containing
gentamicin 5 mg ⁄L for 24 h at 37C in CO2 5%
v ⁄v. S. pneumoniae was identified on the basis of
colony morphology, a-haemolysis and optochin
inhibition. Isolates were stored at )80C for future
serotyping.
Susceptibility to trimethoprim–sulphameth-
oxazole (co-trimoxazole), tetracycline, rifampicin
and clindamycin was determined by disk-diffu-
sion using Mueller–Hinton agar containing sheep
blood 5% v ⁄ v. Susceptibility to penicillin was
determined by disk-diffusion using 1-lg oxacillin
disks. MICs of penicillin were determined by the
Etest method (AB Biodisk, Solna, Sweden). Sus-
ceptibility to erythromycin during the first study
period was determined by disk-diffusion, and
during the second study period by Etest. The
results were interpreted according to CLSI guide-
lines [4]. Isolates showing resistance to three
or more antibiotics were considered to be
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multiresistant. Serotyping of S. pneumoniae was
performed using the Quellung reaction with
Pneumotest kit sera (Statens Serum Institut,
Copenhagen, Denmark), according to the manu-
facturer’s instructions.
Sales data for all antimicrobial agents pre-
scribed for children aged <4 years during 2001–
2002 were obtained from the central database of
the Estonian Health Insurance Fund. Defined
daily doses ⁄ 1000 subjects ⁄day were calculated
as described previously [5].
Univariate analysis was used to identify the
potential risk-factors for colonisation with S. pneu-
moniae, with the chi-square or Fisher’s exact test
used for categorical variables, as appropriate. The
variables that were found to be significant in
univariate analysis were studied by logistic
regression. All statistical tests were performed
using the SPSS statistical package (SPSS Inc.,
Chicago, IL, USA).
In total, 685 children, aged 1–7 years, were
recruited to the study (Table 1), with S. pneumoniae
being isolated from the NP cultures of 299 (44%)
children. The NP colonisation rate for all pneu-
mococci was highest for children aged 1–2 years
(66%) and declined with age; no age group was
associated with carriage of PNSP. The mean
penicillin MIC was 0.012 mg ⁄L. Antimicrobial
resistance was expressed by 220 (74%) isolates;
of these, 12 (4%) were considered to be multi-
resistant. Resistance to trimethoprim–sulpha-
methoxazole (67%) was the most common. In
total, 6% of all isolates were either PNSP or
resistant to erythromycin, but none showed high-
level resistance to penicillin.
In total, 280 isolates were serotyped; 259 (93%)
belonged to 26 serogroups ⁄ serotypes and 21 (8%)
were non-typeable. The most frequently observed
serogroups ⁄ serotypes, in decreasing order, were
19, 23, 6, 15 and 14, which together accounted for
59% of the isolates. Antibiotic consumption rates
in different areas were similar (Table 2). The most
commonly used antibiotics were penicillins,
followed by macrolides and cephalosporins.
According to univariate and multivariate ana-
lysis, residence in Tartu and an age <3 years were
associated with carriage of S. pneumoniae
(OR 1.56, 95% CI 1.13–2.17, and OR 2.5,
95% CI 1.46–4.32, respectively). Risk-factors for
the carriage of trimethoprim–sulphamethoxazole-
resistant S. pneumoniae were age <3 years (OR 1.7,
95% CI 1.00–2.92), day care attendance for
>1 year (OR 1.78, 95% CI 1.19–2.65), exposure to
cigarette smoke at home (OR 1.54, 95% CI 1.08–
2.18) and residence in Tartu (OR 1.71,
95% CI 1.20–2.43).
Overall, the study showed that in Estonia, as in
other northern European countries and Russia,
the prevalence of PNSP from NP samples was low
[2,3], but that there were high levels of resistance
Table 1. Characteristics of children recruited to the study
Characteristic
Total number
of children
n (%)
No. of
Streptococcus
pneumoniae
carriers
n (%)
Gender
Female 339 (49) 148 (44)
Male 346 (51) 151 (44)
Age (years)
1–3 239 (35) 118 (49)
4–5 301 (44) 124 (41)
6–7 145 (21) 57 (39)
Siblings
Yes 406 (59) 175 (43)
No 279 (41) 124 (44)
Cigarette smokers at home
Yes 345 (50) 162 (47)
No 340 (50) 137 (40)
Duration of day care attendance
0–1 year 257 (38) 132 (51)
>1 year 428 (62) 167 (39)
Otitis media in previous 6 months
Yes 87 (13) 31 (36)
No 598 (87) 268 (45)
Antibiotics within previous 6 months
Yes 218 (32) 86 (39)
No 467 (68) 213 (46)
Geographical area
Tartu 292 (43) 144 (49)
Tallinn 191 (28) 66 (35)
Kohtla-Ja¨rve ⁄ Jo˜hvi 202 (29) 89 (44)
Table 2. Antibiotic consumption rate (defined daily doses ⁄ 1000 children) for children aged <4 years in Estonia during
2001–2002
Study location No. of children
No. of DDD ⁄ 1000 children
Total Penicillins Macrolides Cephalosporins TMP-SMX
Tartu 13 115 15.4 7.8 4.5 1.9 1.2
Tallinn 4103 13.3 8.6 2.3 1.5 1.0
Kohtla-Ja¨rve ⁄ Jo˜hvi 1513 11.2 4.3 3.0 0.8 1.1
DDD, defined daily doses; TMP-SMX, trimethoprim–sulphamethoxazole (co-trimoxazole).
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to trimethoprim–sulphamethoxazole, the drug
that was used widely to treat respiratory tract
infections in the past [6]. Recently, Goossens et al.
[7] revealed a significant correlation between
penicillin use and pneumococcal resistance rates
in a European multi-national study, and found
that outpatient antibiotic consumption rates in
Estonia were among the lowest in Europe. Fur-
thermore, as in the present study, the use of oral
cephalosporins was rare. This suggests that
conservative antibiotic prescribing practices are
common in outpatient settings, with penicillins
being preferred to newer macrolides and oral
cephalosporins, and that these two factors may
have played a significant role in the low rate of
PNSP in Estonia. As in previous studies [8,9], age
<3 years and exposure to cigarette smoke from
family members were associated with the carriage
of trimethoprim–sulphamethoxazole-resistant
isolates.
The most common serogroups associated with
NP carriage and invasive disease worldwide are
6, 14, 19 and 23, but differences have been
observed in their distribution among industrial-
ised and non-industrialised countries [10]. These
four serogroups were also commonest in the
present study; however, in contrast to other
industrialised countries, in which 80–90% of
disease-causing strains would be included in or
cross-react with the licensed heptavalent vaccines,
only 64% of NP isolates would be covered by the
vaccine in Estonia [10].
In conclusion, most S. pneumoniae isolates in
Estonia remain susceptible to penicillin and
erythromycin, but high levels of resistance to
trimethoprim–sulphamethoxazole were revealed.
This indicates that penicillins are still the drugs
of choice for treatment of pneumococcal infec-
tions, while the use of trimethoprim–sulpha-
methoxazole for respiratory tract infections
should be avoided. Continuous national monit-
oring of the antimicrobial resistance and
serotype distribution of S. pneumoniae is essential
for designing immunisation strategies and
advising on antibiotic use.
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